Grb7-based molecular therapeutics in cancer

Stephanie C. Pero, Roger J. Daly, David N. Krag

Research output: Contribution to journalReview ArticleResearchpeer-review

34 Citations (Scopus)


Traditional anti-cancer drugs preferentially kill rapidly growing tumour cells rather than normal cells. However, most of these drugs have no preferential selection towards cancer cells and are taken up by the whole body, resulting in significant adverse side effects. Therapeutic molecules that could specifically inhibit undesirable phenotypes are an attractive way of eliminating cancer cells. There is a widespread effort to develop inhibitors against signal transduction molecules that play a key role in the proliferative, migratory and invasive properties of a cancer cell. Grb7 is an adaptor-type signalling protein that is recruited via its Src-homology 2 (SH2) domain to a variety of tyrosine kinases. Grb7 is overexpressed in breast, oesophageal and gastric cancers, and may contribute to the invasive potential of cancer cells. Molecular interactions involving Grb7 therefore provide attractive targets for therapeutic intervention.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalExpert Reviews in Molecular Medicine
Issue number14
Publication statusPublished - 10 May 2003
Externally publishedYes


  • cancer
  • ErbB2
  • Grb7
  • peptide
  • receptor tyrosine kinase
  • SH2 domain
  • signal transduction inhibitor
  • targeted therapeutics

Cite this